Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

被引:26
|
作者
Quenel-Tueux, Nathalie [1 ]
Debled, Marc [1 ]
Rudewicz, Justine [1 ,2 ,3 ,4 ,5 ]
MacGrogan, Gaetan [1 ,2 ,3 ]
Pulido, Marina [6 ,7 ]
Mauriac, Louis [1 ]
Dalenc, Florence [8 ]
Bachelot, Thomas [9 ]
Lortal, Barbara [1 ]
Breton-Callu, Christelle [1 ]
Madranges, Nicolas [1 ]
de lara, Christine Tunon [1 ]
Fournier, Marion [1 ]
Bonnefoi, Herve [1 ,2 ,3 ]
Soueidan, Hayssam [4 ]
Nikolski, Macha [3 ,4 ,5 ]
Gros, Audrey [1 ,2 ,3 ]
Daly, Catherine [10 ]
Wood, Henry [10 ]
Rabbitts, Pamela [10 ]
Iggo, Richard [1 ,2 ,3 ]
机构
[1] Inst Bergonie, Ctr Comprehens Canc, F-33000 Bordeaux, France
[2] INSERM, U916, F-33000 Bordeaux, France
[3] Univ Bordeaux, F-33608 Pessac, France
[4] Univ Bordeaux, Bordeaux Bioinformat Ctr, F-33076 Bordeaux, France
[5] CNRS, UMR5800, Bordeaux Comp Sci Lab, F-33405 Talence, France
[6] INSERM, Clin Invest Ctr, CIC1401, Epidemiol Unit, F-33076 Bordeaux, France
[7] Inst Bergonie, Clin & Epidemiol Res Unit, F-33076 Bordeaux, France
[8] Inst Claudius Regaud, IUCT Oncopole Toulouse, F-31059 Toulouse, France
[9] CLCC Lyon, F-69008 Lyon, France
[10] Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England
关键词
anastrozole; endocrine treatment; fulvestrant; hormone-receptor-positive cancer; large operable or locally advanced breast cancer; neo-adjuvant; NEOADJUVANT ENDOCRINE THERAPY; KI-67 LABELING INDEX; DOUBLE-BLIND; TAMOXIFEN; WOMEN; LETROZOLE; CHEMOTHERAPY; KI67;
D O I
10.1038/bjc.2015.247
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after treatment. Methods: One hundred and twenty post-menopausal patients were randomised to receive 1mg anastrozole (61 patients) or 500mg fulvestrant (59 patients) for 6 months. Genomic DNA copy number profiles were generated for a subgroup of 20 patients before and after treatment. Results: A total of 108 patients were evaluable for efficacy and 118 for toxicity. The objective response rate determined by clinical palpation was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 53.8% (95% CI = 39.5-67.8) in the fulvestrant arm. The breast-conserving surgery rate was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 50.0% (95% CI = 35.8-64.2) in the fulvestrant arm. Pathological responses >50% occurred in 24 patients (42.9%) in the anastrozole arm and 13 (25.0%) in the fulvestrant arm. The Ki-67 score fell after treatment but there was no significant difference between the reduction in the two arms (anastrozole 16.7% (95% CI = 13.3-21.0) before, 3.2% (95% CI = 1.9-5.5) after, n = 43; fulvestrant 17.1% (95% CI = 13.1-22.5) before, 3.2% (95% CI = 1.8-5.7) after, n = 38) or between the reduction in Ki-67 in clinical responders and non-responders. Genomic analysis appeared to show a reduction of clonal diversity following treatment with selection of some clones with simpler copy number profiles. Conclusions: Both anastrozole and fulvestrant were effective and well-tolerated, enabling breast-conserving surgery in over 50% of patients. Clonal changes consistent with clonal selection by the treatment were seen in a subgroup of patients.
引用
收藏
页码:585 / 594
页数:10
相关论文
共 50 条
  • [41] Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
    Masuda, Norikazu
    Inoue, Kenichi
    Nakamura, Rikiya
    Rai, Yoshiaki
    Mukai, Hirofumi
    Ohno, Shinji
    Hara, Fumikata
    Mori, Yuko
    Hashigaki, Satoshi
    Muramatsu, Yasuaki
    Nagasawa, Takashi
    Umeyama, Yoshiko
    Huang, Xin
    Iwata, Hiroji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (03) : 262 - 273
  • [42] Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
    Cristofanilli, Massimo
    Valero, Vicente
    Mangalik, Aroop
    Royce, Melanie
    Rabinowitz, Ian
    Arena, Francis P.
    Kroener, Joan F.
    Curcio, Elizabeth
    Watkins, Claire
    Bacus, Sarah
    Cora, Elsa M.
    Anderson, Elizabeth
    Magill, Patrick J.
    CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1904 - 1914
  • [43] Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)
    Shinzaburo Noguchi
    Matthew J. Ellis
    John F. R. Robertson
    Jackie Thirlwell
    Mehdi Fazal
    Zhimin Shao
    Breast Cancer, 2018, 25 : 356 - 364
  • [44] The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
    Engels, C. C.
    Charehbili, A.
    van de Velde, C. J. H.
    Bastiaannet, E.
    Sajet, A.
    Putter, H.
    van Vliet, E. A.
    van Vlierberghe, R. L. P.
    Smit, V. T. H. B. M.
    Bartlett, J. M. S.
    Seynaeve, C.
    Liefers, G. J.
    Kuppen, P. J. K.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (03) : 587 - 596
  • [45] A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
    Robertson, John F. R.
    Jiang, Zefei
    Di Leo, Angelo
    Ohno, Shinji
    Pritchard, Kathleen I.
    Ellis, Matthew
    Bradbury, Ian
    Campbell, Christine
    BREAST CANCER, 2019, 26 (06) : 703 - 711
  • [46] Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial
    Llombart-Cussac, Antonio
    Ruiz, Amparo
    Anton, Antonio
    Barnadas, Agusti
    Antolin, Silvia
    Ales-Martinez, Jose E.
    Alvarez, Isabel
    Andres, Raquel
    Garcia Saenz, Jose A.
    Lao, Juan
    Carrasco, Eva
    Camara, Carmen
    Casas, Isabel
    Martin, Miguel
    CANCER, 2012, 118 (01) : 241 - 247
  • [47] PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
    Lynce, Filipa
    Saleh, Mervat
    Shajahan-Haq, Ayesha
    Gallagher, Christopher
    Dilawari, Asma
    Hahn, Olwen
    Abu-Khalaf, Maysa
    Cai, Ling
    Pohlmann, Paula
    Mohebtash, Mahsa
    Kamugisha, Lois
    Isaacs, Claudine
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2018, 10 : 190 - 192
  • [48] Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
    Tripathy, Debu
    Im, Seock-Ah
    Colleoni, Marco
    Franke, Fabio
    Bardia, Aditya
    Harbeck, Nadia
    Hurvitz, Sara A.
    Chow, Louis
    Sohn, Joohyuk
    Lee, Keun Seok
    Campos-Gomez, Saul
    Vazquez, Rafael Villanueva
    Jung, Kyung Hae
    Babu, K. Govind
    Wheatley-Price, Paul
    De laurentiis, Michelino
    Im, Young-Hyuck
    Kuemmel, Sherko
    El-Saghir, Nagi
    Liu, Mei-Ching
    Carlson, Gary
    Hughes, Gareth
    Diaz-Padilla, Ivan
    Germa, Caroline
    Hirawat, Samit
    Lu, Yen-Shen
    LANCET ONCOLOGY, 2018, 19 (07): : 904 - 915
  • [49] Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study
    Ruiz-Borrego, Manuel
    Guerrero-Zotano, Angel
    Bermejo, Begona
    Ramos, Manuel
    Cruz, Josefina
    Manuel Baena-Canada, Jose
    Cirauqui, Beatriz
    Rodriguez-Lescure, Alvaro
    Alba, Emilio
    Martinez-Janez, Noelia
    Munoz, Montserrat
    Antolin, Silvia
    Alvarez, Isabel
    Del Barco, Sonia
    Sevillano, Elena
    Ignacio Chacon, Jose
    Anton, Antonio
    Jose Escudero, Maria
    Ruiz, Victoria
    Carrasco, Eva
    Martin, Miguel
    Segui, M. A.
    Ayala, F.
    de la Haba, J.
    Martinez, P.
    Gonzalez, S.
    Lahuerta, A.
    Toral, J. C.
    Martinez de Duenas, E.
    Florian, J.
    Godes, M. J.
    Llorca, C.
    Blancas, I.
    Jara, C.
    Morales, S.
    Arcusa, A.
    Martinez, A.
    Vicente, E.
    de Juan, A.
    Rodriguez, M.
    Garcia, M.
    Garcia, P.
    Bayo, J. L.
    Caranana, V.
    Casinello, J.
    Jolis, L.
    Gil, M.
    Canabate, C.
    Oltra, A.
    Ramirez, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 115 - 125
  • [50] A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
    Massarweh, Suleiman
    Romond, Edward
    Black, Esther P.
    Van Meter, Emily
    Shelton, Brent
    Kadamyan-Melkumian, Vera
    Stevens, Mark
    Elledge, Richard
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (02) : 325 - 332